<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Tianjin Development Holdings ( (HK:0882) ) just unveiled an announcement. Tianjin Development Holdings has disclosed that its indirect subsidiary Tianjin Lisheng Pharmaceutical reported solid preliminary results for 2025, underscoring the growing contribution of its pharmaceutical operations. The company maintains a significant minority stake of just over one‑third in Lisheng, reinforcing its exposure to China’s healthcare and drug markets. Lisheng Pharmaceutical’s unaudited 2025 figures show revenue rising 4.23 percent year on year to RMB1.39 billion, with operating profit more than doubling. Net profit attributable to shareholders surged 126.72 percent to RMB418 million, boosted by market expansion, stronger product sales and dividends from an equity instrument, though net assets per share edged lower as total assets and equity declined slightly. More about Tianjin Development Holdings Tianjin Development Holdings is a Hong Kong‑incorporated conglomerate with interests including pharmaceuticals through its indirect, non‑wholly owned subsidiary Tianjin Lisheng Pharmaceutical, in which it holds about 34.12 percent. Lisheng Pharmaceutical operates in China’s pharmaceutical sector, generating revenue from the sale of medical products and related activities, and is listed on the Shenzhen Stock Exchange under stock code 002393. Average Trading Volume: 570,194 Current Market Cap: HK$2.85B For a thorough assessment of 0882 stock, go to TipRanks’ Stock Analysis page.</div>

513700

516930

159992

Tianjin Development Holdings announced that its subsidiary, Tianjin Lisheng Pharmaceutical, reported strong preliminary results for 2025. Revenue increased by 4.23% year-on-year to RMB1.39 billion, while net profit attributable to shareholders surged 126.72% to RMB418 million. The growth was driven by market expansion and stronger product sales. Despite a slight decline in net assets per share, the results highlight the company's significant stake in China's healthcare market.

Tip Ranks

Penghua CSI HK Connect Health Care Composite ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

TIANJIN DEV

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Lishengpharma

Tianjin Development’s Lisheng Pharma Unit Posts Strong 2025 Preliminary Profit Surge